Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: Myron David Kor who wrote (3872)	5/4/1998 12:10:00 PM
From: Linda Kaplan	Respond to of 7041

Myron: Why would you possibly think that PFE would be worried about a challenge from Vasomax in regard to efficacy, with Viagra's tests providing more than double efficacy of Vasomax's and with Viagra being approved and Vasomax not even filed? I'd assume they'll want to continue to improve their drug, as they are doing by working on its having a much faster response rate, but I shouldn't think that Vasomax would be considered a threat to their market share. Vasomax, according to the poster, is for minimal problems and has a relatively low success rate. Linda